Luisa M. Stamm

4.3k total citations
70 papers, 1.7k citations indexed

About

Luisa M. Stamm is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Luisa M. Stamm has authored 70 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hepatology, 37 papers in Epidemiology and 17 papers in Infectious Diseases. Recurrent topics in Luisa M. Stamm's work include Hepatitis C virus research (46 papers), Hepatitis B Virus Studies (23 papers) and Liver Disease Diagnosis and Treatment (20 papers). Luisa M. Stamm is often cited by papers focused on Hepatitis C virus research (46 papers), Hepatitis B Virus Studies (23 papers) and Liver Disease Diagnosis and Treatment (20 papers). Luisa M. Stamm collaborates with scholars based in United States, Canada and United Kingdom. Luisa M. Stamm's co-authors include Diana M. Brainard, John G. McHutchison, Robert H. Hyland, John R. David, Abhay R. Satoskar, Evguenia S. Svarovskaia, Hongmei Mo, J. Hiroshi Morisaki, Eric J. Brown and Karen Brown and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Luisa M. Stamm

65 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luisa M. Stamm United States	23	1.2k	987	449	253	183	70	1.7k
Isabelle Desombere Belgium	29	1.6k 1.3×	1.4k 1.4×	514 1.1×	569 2.2×	114 0.6×	72	2.4k
Eoin Coakley United States	27	1.3k 1.1×	1.2k 1.3×	1.7k 3.8×	311 1.2×	109 0.6×	66	3.2k
J. Saldanha United Kingdom	22	1.1k 0.9×	912 0.9×	755 1.7×	64 0.3×	316 1.7×	67	1.9k
Giulietta Saletti Germany	17	514 0.4×	334 0.3×	394 0.9×	502 2.0×	53 0.3×	30	1.4k
Annie Cahour France	19	402 0.3×	501 0.5×	332 0.7×	117 0.5×	359 2.0×	44	1.2k
Nico Lelie Netherlands	31	2.1k 1.8×	1.9k 1.9×	696 1.6×	74 0.3×	86 0.5×	54	2.7k
Erwin Sablon Belgium	33	2.6k 2.3×	2.5k 2.5×	422 0.9×	186 0.7×	75 0.4×	79	3.4k
Daniel P. Webster United Kingdom	14	493 0.4×	406 0.4×	330 0.7×	262 1.0×	455 2.5×	23	1.3k
Michael D. Robek United States	29	1.4k 1.2×	936 0.9×	463 1.0×	1.5k 5.8×	70 0.4×	55	2.8k
K Nishioka Japan	19	844 0.7×	763 0.8×	239 0.5×	601 2.4×	49 0.3×	72	1.9k

Countries citing papers authored by Luisa M. Stamm

Since Specialization

Citations

This map shows the geographic impact of Luisa M. Stamm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luisa M. Stamm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luisa M. Stamm more than expected).

Fields of papers citing papers by Luisa M. Stamm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luisa M. Stamm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luisa M. Stamm. The network helps show where Luisa M. Stamm may publish in the future.

Co-authorship network of co-authors of Luisa M. Stamm

This figure shows the co-authorship network connecting the top 25 collaborators of Luisa M. Stamm. A scholar is included among the top collaborators of Luisa M. Stamm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luisa M. Stamm. Luisa M. Stamm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Colson, Amy E., Anthony Mills, Christopher Bettacchi, et al.. (2026). Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. The Lancet. 407(10528). 611–621. 1 indexed citations

Vélez, Juan D., Pallavi Kumar, Andrew Carr, et al.. (2026). Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. The Lancet. 407(10528). 599–610. 1 indexed citations

Peters, Marion G., Man‐Fung Yuen, Norah A. Terrault, et al.. (2023). Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes. Clinical Infectious Diseases. 78(4). 983–990. 5 indexed citations

Gane, Edward, Christian Schwabe, Luisa M. Stamm, et al.. (2023). The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers. Journal of Hepatology. 78. S1161–S1162. 1 indexed citations

Levi, Micha, et al.. (2023). 383. Pharmacokinetics and Safety in Healthy Adults of RSM01, a Novel RSV Monoclonal Antibody, and Population PK Modeling to Support Pediatric Development. Open Forum Infectious Diseases. 10(Supplement_2). 7 indexed citations

Agarwal, Kosh, Jia Xu, Edward Gane, et al.. (2022). Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study. Journal of Viral Hepatitis. 30(3). 209–222. 4 indexed citations

Flamm, Steven L., Eric Lawitz, Brian B. Borg, et al.. (2019). THU-138-High efficacy and improvement in CPT class with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with CPT C decompensated cirrhosis. Journal of Hepatology. 70(1). e221–e222. 2 indexed citations

Bourlière, Marc, Stuart C. Gordon, Eugene R. Schiff, et al.. (2018). Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. The Lancet. Gastroenterology & hepatology. 3(8). 559–565. 18 indexed citations

Borgia, Sergio, Charlotte Hedskog, Bandita Parhy, et al.. (2018). Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. The Journal of Infectious Diseases. 218(11). 1722–1729. 214 indexed citations

10.

Gane, Edward, Christian Schwabe, Robert H. Hyland, et al.. (2016). Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. Gastroenterology. 151(3). 448–456.e1. 50 indexed citations

11.

Gane, Edward, Evguenia S. Svarovskaia, Hadas Dvory‐Sobol, et al.. (2016). Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated with Sofosbuvir/Velpatasvir+GS-9857 for 6 or 8 Weeks. Journal of Hepatology. 64(2). S401–S402. 2 indexed citations

12.

Läwitz, E., Thomas Marbury, Beth J. Kirby, et al.. (2016). The Effect of Renal or Hepatic Impairment on the Pharmacokinetics of GS-9857, a Pan-Genotypic HCV NS3/4A Protease Inhibitor. Journal of Hepatology. 64(2). S613–S613. 2 indexed citations

13.

Younossi, Zobair M., Elzafir Elsheikh, Maria Stepanova, et al.. (2015). Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. Journal of Viral Hepatitis. 22(12). 977–982. 16 indexed citations

14.

Upadhyay, Gaurav A., Justin F. Gainor, Luisa M. Stamm, et al.. (2012). Acute Nonrheumatic Streptococcal Myocarditis: STEMI Mimic in Young Adults. The American Journal of Medicine. 125(12). 1230–1233. 11 indexed citations

15.

Stamm, Luisa M. & Karen Brown. (2004). Mycobacterium marinum: the generalization and specialization of a pathogenic mycobacterium. Microbes and Infection. 6(15). 1418–1428. 49 indexed citations

16.

Stamm, Luisa M., J. Hiroshi Morisaki, Lian‐Yong Gao, et al.. (2003). Mycobacterium marinum Escapes from Phagosomes and Is Propelled by Actin-based Motility. The Journal of Experimental Medicine. 198(9). 1361–1368. 212 indexed citations

17.

Stamm, Luisa M., J. Hiroshi Morisaki, Lian‐Yong Gao, et al.. (2003). Mycobacterium marinum escapes from phagosomes and is propelled by actin-based motility - eScholarship. 198(9). 1361–1368.

18.

Satoskar, Abhay R., et al.. (2000). Interleukin-4-deficient BALB/c mice develop an enhanced Th1-like response but control cardiac inflammation followingBorrelia burgdorferiinfection. FEMS Microbiology Letters. 183(2). 319–325. 12 indexed citations

19.

Stamm, Luisa M., Anjali A. Satoskar, Sudip Kumar Ghosh, et al.. (1999). STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. European Journal of Immunology. 29(8). 2524–2529. 57 indexed citations

20.

Stamm, Luisa M., Anne Räisänen‐Sokolowski, Mitsuhiro Okano, et al.. (1998). Mice with STAT6-Targeted Gene Disruption Develop a Th1 Response and Control Cutaneous Leishmaniasis. The Journal of Immunology. 161(11). 6180–6188. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact